To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10 −4 ), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.
Introduction
The prediction of cancer prognosis is one of the most urgent demands to initiate the treatment of neuroblastoma. As ex-Neuroblastoma is one of the most common solid tumors in pected from the natural course of neuroblastoma, patient age children and originates from the sympathoadrenal lineage of at diagnosis (over or under 1 year of age) is an important progthe neural crest (Bolande, 1974) . Its clinical behaviors are nostic factor (Evans et al., 1971) . Disease stage is also a powheterogeneous. The tumor, when developed in infants, freerful indicator for neuroblastoma prognosis (Brodeur et al., quently regresses spontaneously by inducing differentiation 1993) . Moreover, recent advances in basic research have disand/or programmed cell death. When developed in children covered several molecular markers that are useful in clinical over 1 year of age, however, the tumor is often aggressive and practice, including amplification of the MYCN oncogene acquires resistance to intensive chemotherapy. Although re- (Schwab et al., 1983; Brodeur et al., 1984) , DNA ploidy (Look cent progress in therapeutic strategies against advanced neuet al., 1984; Look et al., 1991) , deletion of chromosome 1p roblastoma has improved patient survival, long-term outcomes (Brodeur et al., 1988) , and TrkA expression (Nakagawara et al., still remain very poor. Furthermore, part of neuroblastomas cat-1992; Nakagawara et al., 1993) . Other indicators also include egorized to the intermediate group (stage 3 or 4 tumors that telomerase (Hiyama et al., 1995) , CD44 (Favrot et al., 1993) , possess a single copy of the MYCN gene) often recurs after pleiotrophin (Nakagawara et al., 1995) , N-cadherin (Shimono et complete response to initial therapy. Such differences in the al., 2000) , CDC10 (Nagata et al., 2000) , and Fyn (Berwanger et final outcomes of the tumor are considered presumably attribal., 2002) . However, the combinations thereof still frequently fail utable to differences in genetic and biological abnormalities, to predict patient outcome. In the post-genome sequence era, which are reflected in the gene and protein expression profiles of the tumor. therefore, the advent of new diagnostic tools has been ex-pected. Recently, the DNA microarray method, applied to com-each gene spot was normalized to eliminate intensity-dependent biases. Since the 5340 genes array contains 260 dupliprehensively demonstrate expression profiles of primary neurocated or multiplicated genes, the expression ratio of such a blastomas and cell lines, has already identified the following: duplicated gene was represented by the average of multiple (1) differences in gene expression between favorable and unfaspots. Based on estimation performance for missing values vorable subsets (Yamanaka et al., 2002; Berwanger et al., (see the Supplemental Data available with this article online) 2002); and (2) differences in gene expression that occur during and on reproduction variance of the duplicated genes, the retinoic acid-induced neuronal differentiation (Ueda, 2001) .
standard deviation for the log ratio of a single gene was suffi-However, a study to predict neuroblastoma prognosis with a ciently small, ranging between about 0.2 and about 0.3 (Figure microarray using a large number of neuroblastoma samples S1A). The scatter plots of the log Cy3/Cy5 fluorescence ratio has never been reported. We have recently isolated 5500 between duplicated gene spots in the 136 experiments and genes from the cDNA libraries, which were generated from prithose between repeated experiments also indicated high remary neuroblastomas, part of which has previously been reproducibility of spotting and experiment (Figures S1B and ported (Ohira et al., 2003a; Ohira et al., 2003b) . In this study, S1C). These suggest that the production of and experiments to identify genes strongly associated with neuroblastoma progby our cDNA microarray are highly reproducible. nosis and to apply them to make a really practical cDNA microarray for neuroblastoma diagnosis, we constructed an in-Supervised classification house, ink-jet-printed cDNA microarray carrying 5340 genes
To develop a statistical tool that predicts the prognosis of a proper to neuroblastoma and applied it to analyze 136 samnew patient with neuroblastoma, we introduced a supervised ples. After selecting genes significantly related to patient progclassification. In the development, we used 136 neuroblastomas, nosis, we made a mini-chip carrying 200 top-ranked genes to randomly selected tumor samples from the neuroblastoma tisapply for the clinic.
sue bank, consisting of 41 stage 1 tumors, 22 stage 2 tumors, There have been many attempts to predict cancer outcome 33 stage 3 tumors, 28 stage 4 tumors, and 12 stage 4s tumors. using microarray. A reliable prediction for outcomes of cancer
The follow-up duration ranged between 3 and 241 months (mepatients naturally demands its reproducibility, and it is quite dian, 56 months, mean, 57.3 months) after diagnosis. The left important to use sound and highly reliable statistical methodolpanel in Figure 2 compiles summary information of each samogies; a complete crossvalidation analysis without introducing ple, including survival time and important prognosis markers any information leakage and an independent test using new (see Experimental Procedures for details). Since variations in samples are necessary. As Ntzani and Ioannidis (2003) pointed follow-up duration generated noises in the supervised classifiout, however, such a careful methodology has often been igcation, we used patient outcome (dead or alive) at 5 years after nored in most microarray studies. We here developed a superdiagnosis as the target label to be predicted. Since the outvised classification method without any information leakage as comes of 40 of 136 samples were unknown at 5 years after a statistic tool and demonstrated that the probabilistic output diagnosis, data for 96 remaining samples were used subseof the analysis defines the molecular signature of neuroquently. When we were interested in short-term outcome preblastoma to predict its prognosis. Although the construction of diction, the target label was set at 2 years after diagnosis, for the statistical tool was based on one of the most reliable statiswhich purpose 126 samples out of the 136 samples were used. tical tests, we also consulted a validation test for an indepen-
We constructed the weighted voting as a supervised classident experiment examining 50 samples (whose RNAs were fier after important genes were selected according to pairwise prepared in an independent laboratory) by using the mini-chip.
F scores. To estimate the prediction accuracy for new data, we The high performance for the outcome prediction by the miniconsulted leave two out (LTO) analysis, which obtains almost chip system suggests the high feasibility of developing a clinunbiased estimation of prediction accuracy for new data while ical tool based on molecular signature.
avoiding overestimation due to information leakage ( Figure  S2A ). Although it is known that the prediction accuracy of a Results supervised classifier depends on the number of genes to be used ( Figure S3 ), the LTO procedure enables us to optimize it Neuroblastoma proper cDNA microarray without introducing information leakage, by using a sample left The whole scheme of our study is summarized in Figure 1 . We out at the outer loop of the double-loop procedure (see Experifirst constructed a neuroblastoma proper cDNA microarray mental Procedures). The crossvalidation accuracy for the 5 harboring the spots of 5340 genes on a slide glass by using a
year prognosis prediction was as high as 88.5% (sensitivity of ceramics-based ink-jet printing system (the 5340 genes sys-86.7% and specificity of 89.4%) ( Table 1 , "Whole cases"). In tem). This in-house cDNA microarray appeared to have overthe LTO analysis, we selected genes and constructed the corcome the previous problems caused by pin-spotting, e.g., unresponding classifier individually for the outcome prediction of even quantity or shape of individual spots on an array. Ten each sample. The average number of the selected genes, n, micrograms each of the total RNA extracted from 136 frozen was 30.7. If we applied the same procedure to the short-term tissues of primary neuroblastomas were labeled with Cy3 dye.
(2 year) prediction, the accuracy, sensitivity, and specificity As a common reference, the mixture of the total RNA obtained were 89.8%, 88.0%, and 90.2%, respectively (data not shown). from four neuroblastoma cell lines with a single copy of MYCN (NB69, NBLS, SK-N-AS, and SH-SY5Y) was labeled with Cy5 dye.
Construction of a probabilistic output We first evaluated the quality of our cDNA microarray, the According to the LTO analysis, we can obtain weighted vote values and the corresponding survival rates. After approximat-5340 genes system. The log Cy3/Cy5 fluorescence ratio of The 5 year survival rate for the former (n = 98) was as good as survival rates, the transformation outputs the reliability of each 94%, while that for the latter (n = 38) was as poor as 33% (p < sample's outcome prediction as a probabilistic output, poste-10 −5 ). When 70 sporadic neuroblastomas were evaluated after rior probability. We suppose each posterior probability, a real excluding the tumors found by mass screening, the 5 year surnumber between 0 and 1, corresponds to the expected 5 year vival rate for the former (n = 40) was 85%, while that for the survival rate. The right upper panel of Figure 2 shows the prelatter (n = 30) was 20% (p < 10 −5 ) ( Figure 3B ). To further evaludictions for the 136 samples as posterior probabilities. Most of ate the efficiency of our system, we calculated the posterior the samples alive at 5 years after diagnosis (blue mark) are value for the intermediate subset of neuroblastoma (type II), found to have posterior values near 1, while most of the dead whose prognosis is usually difficult to predict. As shown in Figsamples (red mark) have those near 0. It is known that it is ure 3C, the survival curves were significantly categorized into difficult to predict the prognosis of neuroblastoma patients of two groups. The 5 year survival rate of patients who were prethe intermediate risk group (the type II subset: stage 3 or 4, dicted as favorable was 89%, while that for unfavorable pawithout amplification of MYCN), denoted by green area. The tients was 36% (p = 0.000067). Since the age at diagnosis (R1 posterior values are likely to take intermediate values near 0.5;
year) is currently used as a poor prognostic factor for the type however, their binarization after being separated by threshold II tumors, we examined the ability of the classifier for the older 0.5 shows good accordance with the actual outcome. Frepatients with type II tumors. Even for such patients whose quencies of posterior values for alive and dead samples are prognosis is difficult to predict, the survival rate (45%) of all 18 shown in the right middle panel. The rate of alive samples patients was divided solely by gene expression into the group among the whole samples, which denotes the actual survival with favorable prognosis (n = 10; 73%) and that with poor outrate, is plotted against each posterior value in the right bottom come (n = 8; 13%) ( Figure 3D ). In addition, if the intermediate panel in Figure 2 ; this panel shows the good correspondence risk group was further separated into stage 3 tumor group and between the posterior value and the survival rate.
stage 4 tumor group, the posterior value was significantly re-Probabilistic outputs are considered to be advantageously lated to the survival, especially for stage 3 tumors ( Figure S5 ). useful as compared with conventional binary outputs when These results suggest that the posterior value obtained by our used in making a clinical assessment and may be considered statistical analysis highly efficaciously allows the classification identical to them if establishing an appropriate threshold value. of patient outcomes, even when the tumor is of the intermedi-The real-valued posterior can be used for categorization into ate type. arbitrary number of groups. For example, dividing the posterior
We further compared our results to existing prognosis markvalues into three by setting thresholds 0.3 and 0.7, we obtain ers in Table 1 and found that the supervised microarray analythree groups whose survival curves are significantly different sis showed the best sensitivity-specificity balance among the from each other; this tertiary categorization provides another prognostic factors for predicting the outcome of neurodefinition of intermediate risk group based only on expression blastoma. When the classifier is combined with the age at diagpatterns ( Figure S4 ). nosis, the disease stage (stage 1, 2, or 4s versus stage 3 or 4) and the MYCN amplification, accuracy, sensitivity, and speci-Comparing the survival curves ficity increased up to 95.8%, 93.3%, and 97.0%, respectively. Figure 3A shows survival curves for favorable and unfavorable patients predicted by the classifier with a binary threshold (0.5).
Although the currently used markers (age, stage, and MYCN) also showed good potential to predict generally but less than the microarray, these exhibited only 64% accuracy of prediction for the type II tumors with R1 year of age (Table 1) . Together with the results of survival analysis, the microarray classifier is revealed to be a powerful predictor to classify such group of neuroblastomas (86% accuracy; Table 1 ).
Practical application of 200 cDNAs microarray and independent test
For the practical use in the clinic, a cDNA microarray system that contains cDNA spots of a relatively small number and hence is easy to treat is expected. According to our gene selection based on the pairwise F score, the numbers of genes that were appropriate for the 5 year and 2 year prognosis prediction for all available samples were 10 and 70, respectively. In order for the system to reserve the applicability to short-term and long-term outcome prediction simultaneously, we selected 200 top-ranked genes according to the pairwise F scores in the 2 year prediction, because the 2 year prediction required larger variety of genes, and then made a smaller cDNA microarray system carrying the 200 genes. The newly designed microarray system (the mini-chip system) was evaluated by being hybridized with 5 g total RNA obtained from 50 independent test samples. To preserve the independence of experimental procedure, these RNAs were prepared and hybridized in a different laboratory from the original experiments of 136 samples with the 5340 genes system (see Experimental Pro- diction was 91.8% (45/49) ( Figure 4C ). These results suggest three things. (1) The supervised classifier obtained by the sta-tumors with a good outcome. Most of the tumors with highly tistical analysis by the 5340 genes system is reproducible even expressed TrkA and hyperdiploidy, as well as tumors detected if it is applied to the data measured by the reduced 200 genes by mass screening, were included in the latter group. Table 2 system. Note that the 50 samples were completely new data shows a list of 41 genes that corresponded to the 70 topfor the classifier in this case. (2) Our procedure to construct scored genes and their p and q values (Storey and Tibshirani, a supervised classifier according to the LTO analysis is also 2003) in the log rank test, since we found that several genes reproducible, because the same procedure was successful in were duplicated in the selected 70 genes. Based on the above making another classifier with a high prediction accuracy when clustering, these genes were categorized into two groups applied to the data taken by the mini-chip system. (3) A simple, (group F and group UF; the gene groups strongly correlated low-cost microarray system, the mini-chip system, is highly with favorable and unfavorable prognosis, respectively) (Figure feasible for predicting the prognosis of neuroblastoma. 5 and Table 2 ). The genes in group F tended to show high levels of expression in the type I tumors, while those in group UF were highly Genes selected for prognosis prediction expressed in the type III tumors. The former contained genes To assess the relationship between the clinically defined subthat were related to neuronal differentiation (tubulin α, periphsets of neuroblastoma and the expression of 70 genes that erin, neuromodulin [GAP43], and HMP19) and genes that were were selected as top scored with 2 year prognosis according to related to catecholamine metabolism (dopa decarboxylase the pairwise F score, we conducted an unsupervised clustering [DDC] , dopamine β-hydroxylase [DBH], and tyrosine hydroxanalysis ( Figure 5 ). As expected, part of the type II (intermediylase [TH]). On the other hand, the latter involved many memate) tumors of patients with a poor prognosis showed an exbers of genes that are related to protein synthesis (ribosomal pression pattern that was similar to that of the type III (unfavorprotein genes such as RPL18A, RPLP0, RPL5, RPL4, and able) tumors, and many of them died. On the other hand, RPL7A as well as translation initiation and elongation factor expression profiles of the remaining type II tumors seemed to be heterogeneous similarly to those of the type I (favorable) genes EEF1G and EIF3S5) and genes that are related to me- tabolism (enolase 1 [ENO1] and transketolase [TKT]). The top outside of the top 10 genes for the 5 year label. Instead, DDX1, which is frequently coamplified with MYCN on chromosome 10 genes selected for the 5 year outcome prediction were RPL18A, ENO1, EEF1G, TUBA3, GNB2L1, ARHGEF7, GCC2, 2p24, was a member of the top 10 genes (UF group) for both of the 2 year and 5 year labels. Confirmation of the differential DDX1 (duplicated), and PRPH. The MYCN gene was also a member of 70 genes (group UF) as expected; however, it was expression of the selected genes was further conducted by Although 70 clones were selected as important genes for the supervised classifier, duplicated and multiplicated clones are omitted in this table. The 41 genes are classified into two groups, "F > UF" and "F < UF," when the expression in favorable samples is higher than that in unfavorable samples, and vice versa, respectively. In each group, genes are sorted by log rank p values. The log rank p value for each gene was calculated by comparing survival curves of two patient groups, in which the expression of the gene is higher and lower, respectively, than the median over the samples. A "q value" of a gene denotes the estimated false discovery rate among the genes whose p value is the same or smaller than that of the gene, and is a p-like value while incorporating multiplicity of the statistical test.
using representative 16 favorable and 16 unfavorable tumor favorable histology tumor) for peripherin protein in neurites. Peripherin was completely negative in the unfavorable histolsamples that were independent of the 136 samples used in the ogy tumor of undifferentiated subtype (Figure S7 , UF&NA). present analysis, by semiquantitative RT-PCR ( Figure S6; refer These results indicate the reliability of our gene selection. In also to Ohira et al., 2003a) . We also conducted immunohistothe log rank test, p values of 18 of 20 genes in group F and of chemical analysis for peripherin antibody using tissue sections all 21 genes in group UF were less than 0.05 (Table 2) , indicatprepared from primary neuroblastoma with favorable and unfaing that these 39 genes can be independent prognostic factors vorable histology, since peripherin gene is a member of the top for primary neuroblastomas. 10 genes for both 2 year and 5 year outcome prediction (Table  2) . Peripherin protein was positively detected in the cytoplasm of neuroblastic cells as well as neuritis in all three favorable Discussion histology tumors ( Figure S7, FH&NA) . Two unfavorable histology tumors with poorly differentiated subtype, regardless of Our study has disclosed the molecular signature of neuroblastoma that predicts patient outcomes by using RNA ob-MYCN status, showed sporadic staining (less than 20% of the tained from 136 primary neuroblastomas. The highly reliable to the prediction of intrahepatic recurrence within 1 year after statistical analysis by using a neuroblastoma proper cDNA curative surgery for hepatocellular carcinoma patients. Almicroarray harboring 5340 genes based on an electrically conthough their predictor showed sufficiently high accuracy in an trolled ceramics-based ink-jet method led us to design a cDNA independent test with 27 samples, their crossvalidation promicroarray system harboring 200 genes, which is applicable to cedure excluded the validation of the determination process of short-term (2 year) and long-term (5 year) prognosis predicthe number of optimum genes (steps 5 and 6 in their algotions for neuroblastoma. rithm). The high crossvalidation accuracy of 100% may be an Our study demonstrated that the supervised classifier prooverestimation due to the information leakage. duced by the 5340 genes system provided a high accuracy
According to the recent study that evaluated statistical meth-(88.5%) for the 5 year outcome prediction, with a good balance odologies used by microarray studies published between 1995 between sensitivity (86.7%) and specificity (89.4%). Although and April 2003, the three papers above were the only ones age at diagnosis, disease stage, MYCN amplification, and pathat reported both fairly sound crossvalidation analyses and tients found by mass screening have been useful prognostic independent tests (Ntzani and Ioannidis, 2003) . Our LTO promarkers currently used at the bedside, most of them have cedure includes the validation process of the number of genes either high sensitivity or high specificity ( Table 1 ). The microarused in the classifier and hence is a complete crossvalidation ray analysis showed the best sensitivity-specificity balance process. In addition, the obtained classifier was applied to the among the prognostic factors for predicting the outcome of 50 independent samples that were measured by the reduced neuroblastoma. When the classifier is combined with the age 200 genes system. This is a stronger test than usual indepenat diagnosis, the disease stage (stage 1, 2, or 4s versus stage dent tests but is important for the development of a practical 3 or 4) and the MYCN amplification, accuracy, sensitivity, and system at the bedside. In addition, our LTO analysis achieved specificity increased up to 95.8%, 93.3%, and 97.0%, respecan almost unbiased estimation of the accuracy. Our crossvalitively. Furthermore, the intermediate subset of neuroblastomas dation analysis using the LTO procedure, the independent test (type II), for which a long-term prognosis is usually difficult to of the classifier, and the validation of the procedure itself within make, was also categorized by microarray analysis into groups a new experimental environment using the mini-chip system of patients with a favorable prognosis and those with an unfaexhibited one of the most conservative and reliable statistical vorable prognosis. These successful results led us to produce methodologies. In addition, our gene selection procedure aca more practical tool at the bedside, the mini-chip system, cording to the pairwise F score tries to extract correlation whose accuracy, sensitivity, and specificity were 87.8%, 76.5%, structures among genes, based on an idea similar to the exand 93.8%, respectively, when the classifier constructed by the haustive optimization method used in Iizuka et al. (2003) , is 5340 genes system was applied to 50 independent samples beneficial in enhancing the applicability of the mini-chip system measured by the mini-chip system, and were 91.8%, 82.4%
to various prediction problems, namely, short-term and longand 96.9%, respectively, when another classifier was conterm outcome predictions. structed by applying the LTO procedure to the same data In addition to high accuracy, another advantage of our (Figure 4) . method is to provide a type of predictive information beyond It is well recognized now that gene expression analyses for the conventional binary prediction like favorable and unfavorcancer prognosis prediction should pay close attention to the able, which is ambiguous. The probabilistic output based on reproducibility of obtained results. A complete crossvalidation the hypothetical distribution obtained by the LTO analysis, the analysis without introducing any information leakage and an posterior probability, was found to show good accordance with independent test using new samples are necessary. Although actual survival rate (right bottom panel in Figure 2 ); this enables the determination of the appropriate number of genes used in us to make a simple interpretation of the output: a patient with supervised classifiers should be included in the validation proa posterior value of 0.8 has 80% chance for the 5 year survival, cedure, it has often been ignored in most microarray studies.
for example. Moreover, by calculating posterior probabilities for van 't Veer et al. (2002) applied the supervised classification to various future time points, a survival chance curve for each the breast cancer gene signature, which is predictive of a short patient can be depicted ( Figure 6 ). Although the follow-up interval to distant metastases in 78 patients who were initially period of patient "S057" is 2 years, and the patient is alive at devoid of local lymph node metastasis. Although their crossthis time, the individual survival chance curve says that his/her validation analysis without the validation of the number of survival chance estimated from the gene expression pattern genes correctly predicted the actual outcome of disease for 63 at diagnosis will get smaller than 50% at about 3 years after of 78 patients (80.7%), the accuracy was worse when a comdiagnosis. Such an individual survival chance curve can be plete validation was applied (73.1%). This difference suggests used in choosing a suitable therapeutic protocol. that even small information leakage may lead to overestimation Another advantage of our method is that the probabilistic of the accuracy. Beer et al. (2002) applied the supervised clasoutput is very stable in the presence of noise. Even when an sification to the outcome prediction of lung adenocarcinoma. artificial noise, whose variance is as large as the estimated Their statistical analysis was complete without any information noise variance of microarray, was added to expression profile leakage. They did not report the prediction accuracy, but we data, prognosis prediction did not degrade very much (Figure  estimated the accuracy to be about 70% from the data in their S8). This robustness was confirmed when the noise variance paper and found that the prediction by their supervised classiwent up to 1.0, which was sufficiently greater than the actual fier was not very superior to that by existing prognosis markers. Iizuka et al. (2003) applied the supervised classification reproduction noise level of 0.4 ( Figures S1A-S1C) .
the probabilistic output is highly robust against noises that may be involved in test samples (described above); this can be the major reason for the high prediction accuracy when the classifier constructed by the 5340 genes system was applied to the data taken by the mini-chip system. The impact of the selected genes is strong. The genes with the highest score in F group genes (F > UF) were tubulin α members (TUBA3 and K-ALPHA-1, which corresponds to TUBA1), which have never been reported to be prognostic factors in neuroblastoma. Their prognostic significance has also been confirmed by RT-PCR in primary tumors (data not shown). The high expression of TUBA1 in neuronal cells is associated with axonal outgrowth during development as well as with axonal degeneration after axotomy in adult animals (Knoops and Octave, 1997) . The expression of TUBA3 has been reported to be restricted to adherent, morphologically differentiated neuronal and glial cells (Hall and Cowan, 1985) . We have also found that high expression of tubulin tyrosine ligase and enhanced tubulin tyrosination/detyrosination cycle are associated with neuronal differentiation in neuroblastomas with favorable prognosis (Kato et al., 2004) . Thus, high mRNA expression of TUBA genes in favorable neuroblastoma may reflect differentiated status of tumors. ARHGEF7, Rho guanine nucleotide exchange factor 7, activates Rho proteins by exchanging bound GDP for GTP and can induce membrane ruffling. In our previous paper, we found that many family members of such G protein-related genes are highly expressed in origin. This protein is known to be a marker of terminal neualive or dead at that time after diagnosis, respectively. For example, the ronal differentiation; however, its functional role in neuropatient "S108," who died at 40 months, is predicted as 100% alive at 0.5 blastoma has been elusive. The previous evidence indicates year and 52% alive at 5 year, solely from the microarray analysis at the that peripherin is transcriptionally upregulated by treatment diagnosis with NGF, an important neurotrophin in neuroblastoma, and that the protein product is directly phosphorylated by NGF receptor, TrkA (Aletta et al., 1989) . Thus, peripherin may play an important role as one of the signal transduction components The high outcome predictability of our system is attributable involved in elaboration and maintenance of neuronal differentito multiple reasons. The quality of tumor samples is high beation. In the UF gene group, many ribosomal protein-related cause (1) an appropriate system was established for our neurogenes are selected. GNB2L1, a receptor for activated C-kinase blastoma tissue bank, and (2) handling of tumor tissues is RACK1, is implicated in linking between PKC signaling and rirather uniform at each hospital, in which informed consent was bosome activation (Ceci et al., 2003) . The DDX1 gene, which obtained. An array, produced by a new apparatus equipped is frequently coamplified with the MYCN gene in advanced with a piezo microceramic pump, generates highly reproducneuroblastomas (Godbout and Squire, 1993; Noguchi et al. , ible signals. The noncontact spotting method makes the spot 1996), is also a member of this group. Its protein product is a shape almost a perfect circle. Consequently, the spot excels in putative RNA helicase and is implicated in a number of cellular signal uniformity. We did not conduct microdissection of the processes involving alteration of RNA secondary structure 136 tumor samples, because the stromal components of the such as translation initiation, nuclear and mitochondrial splictumor, e.g., Schwannian cells, are already known to be very ing, and ribosome and spliceosome assembly. DDX1 is ranked important to characterize its biology (Ambros and Ambros, at a higher score than the MYCN gene, which is concordant 1995; Ambros and Ambros, 2000). Therefore, a good combinawith the previous reports describing that MYCN mRNA exprestion or selection of these procedures may have provided high sion is a weaker prognostic marker than its genomic amplificaoutcome predictability. In addition, the high predictability was tion (Slavc et al., 1990) . Another important prognostic factor, reliably confirmed by the complete crossvalidation analysis and TrkA, is not included in the top 70 genes but in the 90 (in the the independent test. The probabilistic output based on the top 20 genes when the 5 year label was used) (data not LTO analysis can provide a new type of information that will shown), probably due to its relatively low levels of mRNA expression as compared with those of other genes. The prognos-improve the therapeutic decision at the bedside. In addition, each hospital. Shimada's classification (Shimada et al., 1984) was pertic effect of TrkA expression may be compensated by other formed in 62 out of 136 cases. The macroscopic necroses in the tumor genes which are affected or regulated by TrkA intracellular sigwere excluded from the tissue sampling for molecular analysis. We used naling. Similarly, MYCN-regulated genes such as ribosomal for the microarray analysis only the tumor samples whose adjacent tissues genes, translation initiation and elongation factors, and laminin contained more than 70% tumor cells in the thin sections stained with hereceptor may compensate the effect of MYCN gene expression matoxylin-eosin. For independent test, 50 (19 were found by mass screenin aggressive tumors. It is intriguing that high mRNA expression ing and 31 were clinically found) tumors (15 of stage 1, 6 of stage 2, 9 of stage 3, 14 of stage 4, and 6 of stage 4s) were used. of p53 gene is also strongly related to unfavorable outcome.
Total RNA was extracted from each frozen tissue according to the AGPC Although p53 mutation is rare in primary neuroblastomas, and method (Chomczynski and Sacchi, 1987) . RNA integrity, quality, and quanits gene product frequently accumulated in cytoplasm, an untity were then assessed by electrophoresis on the Agilent RNA 6000 naknown mechanism that upregulates p53 expression in aggresnochip using Agilent 2100 BioAnalyzer (Agilent Technologies, Inc.). sive tumors may exist.
Our results showed that the decision by majority by the cDNA microarray experiments genes selected based on microarray data alone can be a prog-
We previously obtained approximately 5,000 genes after selecting from 10,000 clones randomly picked up from the mixture of oligo-capping cDNA nostic indicator comparative to the existing prognostic marklibraries, which were generated from three primary neuroblastomas with a ers, and that the addition of the microarray data to the prognofavorable outcome (stage 1; high TrkA expression and a single copy of sis markers improved the outcome prediction ( possible. Our further validation by hybridizing RNA obtained Ten micrograms each of total RNA were labeled with the CyScribe RNA labeling kit in accordance with the manufacturer's manual (Amersham Pharfrom 50 fresh neuroblastomas on the 200 cDNAs microarray in macia Biotech), followed by probe purification with the Qiagen MinElute a completely independent laboratory indicated that our predic-PCR purification kit (Qiagen). We used a mixture of equal amounts of RNA tion system is consistent and feasible. Therefore, the applicafrom each of four neuroblastoma cell lines (NB69, NBL-S, SK-N-AS, and tion of a highly qualified cDNA microarray at the bedside may SH-SY5Y) as a reference. RNAs extracted from primary neuroblastoma tisbring tailored medicine that allows better treatment of neurosues and RNAs of the reference mixture were labeled with Cy3 and Cy5 blastoma patients. dye, respectively, and were used as probes together with yeast tRNA and polyA for suppression. Subsequent hybridization and washing were con-Experimental procedures ducted as described previously (Takahashi et al., 2002; Yoshikawa et al., 2000) . Hybridized microarrays were scanned using the Agilent G2505A con-Patients and tumor specimens focal laser scanner (Agilent Technologies, Inc.), and fluorescent intensities Fresh, frozen tumor tissues were sent to the Division of Biochemistry, Chiba were quantified using the GenePix Pro microarray analysis software (Axon Instruments, Inc.). The procedure of this study was approved by the Institu-Cancer Center Research Institute, from a number of hospitals in Japan tional Review Board of the Chiba Cancer Center. (1996) (1997) (1998) (1999) (2000) (2001) (2002) . Informed consent was obtained at each institution or hospital.
After selecting genes strongly related to the prognosis of patients with We randomly selected tumor samples from this neuroblastoma tissue bank neuroblastoma (at 2 years and at 5 years after diagnosis), we constructed and then successfully conducted hybridization in 136 neuroblastomas cona 200 cDNAs microarray on glass slides by the same procedure described sisting of 41 stage 1 tumors, 22 stage 2 tumors, 33 stage 3 tumors, 28 stage above (the mini-chip system). For the independent test using 50 samples, 4 tumors, and 12 stage 4s tumors. Among the 136 fresh neuroblastomas, tumor RNA preparation, probe labeling, and hybridization were conducted seventeen tumors were obtained at the delayed primary surgery after giving in a completely different laboratory from the original 136 hybridization. In chemotherapy, but the other 119 tumors were resected by biopsy or surgery this independent test, 5 g each of total RNA were used for labeling. without giving any therapy. After surgery, patients were treated according to the previously described common protocols (Kaneko et al., 1998) . Bio-Data preprocessing logical information on each tumor, including MYCN gene copy number, TrkA
To remove chip-wise biases of a microarray system, we used the LOWESS gene expression, and DNA ploidy, was analyzed in our laboratory, as denormalization (Cleveland, 1979) . When the Cy3 or Cy5 strength for a clone scribed previously (Hishiki et al., 1998) . All the tumors were classified acwas smaller than 3, strength was regarded as abnormally small, and the log cording to the International Neuroblastoma Staging System (INSS) (Brodeur expression ratio of the corresponding clone was treated as a missing value. et al., 1993) . The stage 4s neuroblastoma shows a special pattern of clinical
The rate of such missing entries was less than 1%. After normalizing the behaviors, and the tumor itself, as well as its widespread metastases to the 5340 (genes) by 136 (samples) log expression matrix and removing missing skin, liver, or bone marrow, usually regresses spontaneously. For a better values, each missing entry was imputed to an estimated value by Bayesian understanding of statistical results, we introduced Brodeur's classification principal component analysis, which was developed previously (Oba et al., of neuroblastoma subsets: type I (stages 1, 2, or 4s; a single copy of MYCN; . blue marks in Figure 2 ), type II (stage 3 or 4; a single copy of MYCN; green marks in Figure 2 ), and type III (all stages; amplification of MYCN; red marks in Figure 2 ) . Among 136 tumors that we
Supervised machine learning and LTO crossvalidation
The 96 samples, whose prognosis at 5 years after diagnosis had been suc-analyzed, 66 were found by mass screening of urinary catecholamine metabolites at the age of 6 months, which has been performed nationwide in cessfully checked, were used to train a supervised classifier that predicts the 5 year prognosis of a new patient. When we considered the short-term Japan from 1984 to 2004 (Sawada et al., 1984 . The follow-up duration ranged between 3 and 241 months (median, 56 months; mean, 57.3 prediction, 126 samples whose 2 year prognosis is known were used. Selection of the genes that are related to the classification is an important months) after diagnosis. All diagnoses of neuroblastoma were confirmed by the histological assessment of a surgically resected tumor specimen at preprocess for reliable prediction. We omitted the genes whose standard deviation of the log ratios for the genes obtained over 136 experiments was stroma-poor) and included three favorable histology tumors (poorly differentiated subtype without MYCN amplification [one case]; differentiated smaller than 0.36, so that 1000 genes remained, because the background subtype without MYCN amplification [two cases]) and three unfavorable hisnoise level was about 0.2-0.3. After the gene screening, the genes were tology tumors (undifferentiated subtype without MYCN amplification [one scored by the pairwise F score, which is a modification of a pairwise correcase]; poorly differentiated subtype with MYCN amplification [one case]; lation method (Bo and Jonassen, 2002) , to conduct gene ranking in an atpoorly differentiated subtype without MYCN amplification). All tumor tissues tempt not only to obtain higher discrimination accuracy by using a smaller were obtained prior to chemotherapy and irradiation therapy. Four micron number of genes but also to reserve the applicability to various outcome thick sections from the formalin-fixed, paraffin-embedded samples of these prediction by the set of selected genes (see the Supplemental Data).
tumors were treated according to the protocol described previously (Kato We used a well-established technique in the supervised classification et al., 2004) . As for the negative controls, normal goat immunoglobulins (prognosis prediction), that is, weighted voting with linear discriminators,
(1:500 dilution; Vector Laboratories) were applied as the primary antibody. where each weight value was calculated as the signal-to-noise ratio (Golub et al., 1999) . In the weighted voting, only n genes with the largest pairwise F score were used. The number of top genes, n, strongly affects the predic-Supplemental data tion accuracy ( Figure S3 ) as found in various microarray studies and hence
The Supplemental Data include Supplemental Experimental Procedures should be determined such to maximize the leave one out (LOO) crossvaliand ten supplemental figures and can be found with this article online at dation accuracy. However, a naive determination process of n may introhttp://www.cancercell.org/cgi/content/full/7/4/337/DC1/. duce information leakage, and the accuracy optimized by the LOO crossvalidation involves overestimation. To avoid such an overestimation, we consulted a LTO analysis. The LTO analysis was constituted of inner and Acknowledgments outer loops of LOO ( Figure S2A) ; the gene number n was optimized by the LOO crossvalidation repeating the inner loops, and the optimized classifier
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